Description

SomaLogic, Inc., established in 1999 and based in Boulder, Colorado, is a prominent player in the United States specializing in the identification of protein biomarkers and clinical diagnostic solutions. The company's core technological offering centers on its proprietary slow off-rate modified aptamers, known as SOMAmers – these are uniquely engineered nucleic acid-based reagents designed for precise protein binding. Complementing this, SomaLogic provides SomaScan services, a platform that enables the high-throughput detection and quantification of numerous protein levels within diverse and complex biological samples. This integrated SOMAmers/SomaScan technology empowers researchers to pinpoint crucial protein biomarker signatures across various biological sample types, which are then leveraged for advancements in drug discovery and development efforts. Furthermore, the valuable biomarker insights generated by SomaScan find diagnostic applications in a range of health areas, including cardiovascular and metabolic disorders, nonalcoholic steatohepatitis, and general wellness evaluations. Beyond its core services, SomaLogic also supplies SomaSignal products for research use and as laboratory-developed tests. The company primarily caters to research and clinical clientele, with a significant focus on pharmaceutical and biotechnology companies, as well as academic research institutions. Through its offerings, SomaLogic contributes to accelerating drug development, enhancing the analysis of clinical trials, and deepening our understanding of human biology by investigating intricate protein-protein and protein-gene networks.